Biological & Clinical Efficacy of Subcutaneous Recombinant Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts Under Active Antiretroviral Therapy
|Effective start/end date||11/11/02 → 11/30/09|
- NOVARTIS PHARMACEUTICALS CORPORATION
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.